IRCT20170122032121N8
Recruiting
Phase 1
Safety and efficacy evaluation post intravenous infusion of activated NK cells in recurrent and refractory of high-risk neuroblastoma patients: a phase I/IIa clinical trial
Kian immune cell company0 sites10 target enrollmentTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kian immune cell company
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •High\-risk neuroblastoma that is resistant to standard induction therapy based on COG (Children’s Oncology Group) criteria (according to INRG criteria and having received at least 4 cycles of multi\-drug induction chemotherapy, and not responding to conventional treatments).
- •Evidence of relapse or progression of neuroblastoma after autologous peripheral blood stem cell transplantation or aggressive therapy.
- •A minimum life expectancy of 6 months.
- •Patients must have a pathological diagnosis of neuroblastoma and/or confirmation of tumor cells in the bone marrow with increased urinary catecholamines.
- •Measurable residual disease based on imaging findings using Curie scoring or MIBG or PET imaging criteria (1: measurable tumor of at least 10 mm in one dimension on MRI or CT scan with positive uptake on I\-123 MIBG scan (MIBG avid”) or 2\) increased FDG uptake on 18F\-FDG PET\-CT or PET\-MRI (PET avid”)).
Exclusion Criteria
- •Insufficient bone marrow function: Platelet count \> 50,000/µL, independent of transfusion (no platelet transfusion within one week).Absolute neutrophil count (ANC) maximum of 500 per microliter.Hemoglobin \> 10 grams per deciliter.
- •Insufficient liver function: Plasma bilirubin level more than 1\.5 times the upper limit of normal (ULN).SGPT (ALT) at least three times the upper limit of normal (a level of 45 units per liter is considered the upper limit of normal).
- •Insufficient kidney function: Creatinine clearance or estimated radioisotope GFR \< 70 ml/min/1\.73m².Plasma creatinine level more than 1\.5 times the upper limit of normal based on age/gender.
- •Insufficient central nervous system functionIf seizures are present, entry into the study is not possible if seizures are not well controlled with anticonvulsant drugs.CNS toxicity \> Grade 2\.
- •Insufficient cardiovascular functionShortening fraction \< 27% by ECHO OREjection fraction \< 50% by ECHO or gated radionuclide study.
- •Insufficient pulmonary functionEvidence of dyspnea at rest.Exercise intolerance.Chronic need for oxygen and room air pulse oximetry \< 94% if pulse oximetry evaluation is clinically indicated.Presence of current pleural or pericardial effusion.
- •Inability to tolerate new treatment due to emergency conditions.
- •Elevated catecholamines (more than twice the ULN) or sole involvement of bone marrow (bone marrow positive for NB as the only evaluable disease without confirmatory pathology report).
- •Receiving 0\.5 mg/kg/day of systemic steroids (equivalent to prednisone) for at least 7 days before enrollment.
- •Receiving CYP3A4 inducers or inhibitors at least 7 days before study enrollment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Evaluating the effects of intravenous immunoglobulin (IVIG) in COVID-19 patientsIRCT20151227025726N20Shahid Beheshti University of Medical Sciences80
Active, not recruiting
Phase 1
Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency AnemiaEUCTR2019-003821-70-PLAmerican Regent, Inc.10
Recruiting
Phase 2
Investigating the effect of the bone marrow-drived mesenchymal stem cells in MS patients under fingolimod therapy.IRCT20191004044975N1Vice-presidency for science and technology120
Completed
Not Applicable
Assessment on safety of intravenously administered trastuzumab with 100 ml saline solution in HER2 positive breast cancerBreast cancerJPRN-UMIN000006710Shiga University of Medical Science30
Not yet recruiting
Phase 4
Comparing Tramadol vs Paracetamol for Pain Relief in Acute Pancreatitis: A Randomized Controlled TrialCTRI/2024/06/068751DR ABHIJEET SHRIDHAR